PT  - JOURNAL ARTICLE
AU  - Collier, Dami A.
AU  - Ferreira, Isabella A.T.M.
AU  - Datir, Rawlings
AU  - Meng, Bo
AU  - Bergamaschi, Laura
AU  - ,
AU  - Elmer, Anne
AU  - Kingston, Nathalie
AU  - Graves, Barbara
AU  - Smith, Kenneth GC
AU  - Bradley, John R.
AU  - Lyons, Paul A.
AU  - Ceron-Gutierrez L, Lourdes
AU  - Barcenas-Morales, Gabriela
AU  - Doffinger, Rainer
AU  - Wills, Mark
AU  - Gupta, Ravindra K.
TI  - Age-related heterogeneity in Neutralising antibody responses to SARS-CoV-2 following BNT162b2 vaccination
AID  - 10.1101/2021.02.03.21251054
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.03.21251054
4099  - http://medrxiv.org/content/early/2021/02/05/2021.02.03.21251054.short
4100  - http://medrxiv.org/content/early/2021/02/05/2021.02.03.21251054.full
AB  - Vaccines remain the cornerstone for containing the SARS-CoV-2 pandemic. mRNA vaccines provide protection in clinical trials using a two-dose approach, separated by a three-week gap. Here we assessed real world immune responses following vaccination with mRNA-based vaccine BNT162b2. Following the first and second doses of the BNT162b2 vaccine, we measured IFNγ T cell responses, both total IgG Spike/ IgG Spike RBD and neutralising antibody responses to Spike in sera using a lentiviral pseudotyping system. Median age was 82 amongst 26 participants. Three weeks after the first dose a lower proportion of participants over 80 years old achieved adequate neutralisation titre of >1:4 for 50% neutralisation as compared to those under 80 (8/15 versus 11/11, p<0.05). Mean neutralisation titres in this age group after the first dose were lower than in younger individuals (p<0.05). Following the second dose, neutralising antibody response 50% titres were above 1:4 in all individuals and there was no longer a difference by age grouping. A significant proportion of individuals over 80 appear to require a second dose of vaccine, given in this study at three weeks, to achieve virus neutralisation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNIHR BioresourceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the East of England Cambridge Central Research Ethics Committee (17EE0025).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request from the corresponding author